172 related articles for article (PubMed ID: 38381537)
1. Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD.
Murphy WA; Diehl AM; Loop MS; Fu D; Guy CD; Abdelmalek MF; Karachaliou GS; Sjöstedt N; Neuhoff S; Honkakoski P; Brouwer KLR
Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38381537
[TBL] [Abstract][Full Text] [Related]
2. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
Okushin K; Tsutsumi T; Enooku K; Fujinaga H; Kado A; Shibahara J; Fukayama M; Moriya K; Yotsuyanagi H; Koike K
J Gastroenterol; 2016 Aug; 51(8):808-18. PubMed ID: 26601667
[TBL] [Abstract][Full Text] [Related]
3. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
[TBL] [Abstract][Full Text] [Related]
4. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
[TBL] [Abstract][Full Text] [Related]
5. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.
Clarke JD; Novak P; Lake AD; Hardwick RN; Cherrington NJ
Liver Int; 2017 Jul; 37(7):1074-1081. PubMed ID: 28097795
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Novel Fluorescent Bile Salt Derivatives for Studying Human Bile Salt and Organic Anion Transporters.
Leuenberger M; Häusler S; Höhn V; Euler A; Stieger B; Lochner M
J Pharmacol Exp Ther; 2021 Jun; 377(3):346-357. PubMed ID: 33782042
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
8. Obstructive cholestasis induces TNF-alpha- and IL-1 -mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2.
Donner MG; Schumacher S; Warskulat U; Heinemann J; Häussinger D
Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1134-46. PubMed ID: 17916651
[TBL] [Abstract][Full Text] [Related]
9. Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.
Zhang Y; Lickteig AJ; Csanaky IL; Klaassen CD
Toxicol Sci; 2017 Dec; 160(2):351-360. PubMed ID: 28973556
[TBL] [Abstract][Full Text] [Related]
10. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
[TBL] [Abstract][Full Text] [Related]
11. Organic anion-transporting polypeptide 1a4 (Oatp1a4) is important for secondary bile acid metabolism.
Zhang Y; Csanaky IL; Selwyn FP; Lehman-McKeeman LD; Klaassen CD
Biochem Pharmacol; 2013 Aug; 86(3):437-45. PubMed ID: 23747753
[TBL] [Abstract][Full Text] [Related]
12. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.
Laddha AP; Dzielak L; Lewis C; Xue R; Manautou JE
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167037. PubMed ID: 38295624
[TBL] [Abstract][Full Text] [Related]
13. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.
Keitel V; Burdelski M; Warskulat U; Kühlkamp T; Keppler D; Häussinger D; Kubitz R
Hepatology; 2005 May; 41(5):1160-72. PubMed ID: 15841457
[TBL] [Abstract][Full Text] [Related]
14. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
[TBL] [Abstract][Full Text] [Related]
15. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
16. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus.
Jung Y; Koo BK; Jang SY; Kim D; Lee H; Lee DH; Joo SK; Jung YJ; Park JH; Yoo T; Choi M; Lee MK; Kang SW; Chang MS; Kim W; Hwang GS;
Liver Int; 2021 Dec; 41(12):2892-2902. PubMed ID: 34358397
[TBL] [Abstract][Full Text] [Related]
17. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
Hall Z; Bond NJ; Ashmore T; Sanders F; Ament Z; Wang X; Murray AJ; Bellafante E; Virtue S; Vidal-Puig A; Allison M; Davies SE; Koulman A; Vacca M; Griffin JL
Hepatology; 2017 Apr; 65(4):1165-1180. PubMed ID: 27863448
[TBL] [Abstract][Full Text] [Related]
18. Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures.
Liu J; Lu H; Lu YF; Lei X; Cui JY; Ellis E; Strom SC; Klaassen CD
Toxicol Sci; 2014 Oct; 141(2):538-46. PubMed ID: 25055961
[TBL] [Abstract][Full Text] [Related]
19. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
[TBL] [Abstract][Full Text] [Related]
20. Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes.
Steinman JB; Salomao MA; Pajvani UB
Liver Int; 2021 Nov; 41(11):2534-2546. PubMed ID: 34328687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
